Fig. 5: FOXK2 SUMOylation is impaired in paclitaxel-resistant cells.
From: SUMOylation modulates FOXK2-mediated paclitaxel sensitivity in breast cancer cells
a MCF-7 TaxR cells were transfected with the empty vector (pCMV5), wild-type FOXK2 and SUMO-mutant FOXK2 vector (K527/633 R), seeded in 96-well plates and treated with increasing concentrations of paclitaxel. After 24, 48 and 72 h of incubation with the drugs, cell viability was assessed by SRB assay. Bars represent average ± s.d. from three independent experiments. Statistical significance was determined by Student’s t-test (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001, significant). b MCF-7 TaxR cells were transfected with the empty vector (pCMV5), wild-type FOXK2 and SUMO-mutant FOXK2 vector (K527/633 R), seeded in 6-well plates and treated with increasing concentrations of paclitaxel. After 48 h of incubation with the drugs, cells were culture in fresh media, grown for around 14 days and stained with crystal violet. The graphs are representative of three experiments. Statistical significance was determined by Student’s t-test (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001, significant)
